Rademikibart for Acute COPD Exacerbation (Seabreeze STAT COPD)

Market
100%75%50%25%0%Apr 26 • YES 34.0%Apr 26
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
4/1/26
Study Completion
5/1/26
Sponsor
Connect Biopharm LLC
Ticker
Unavailable
Type
Phase 2
Trial Status
Recruiting
Trial Size
160
NCT
NCT06940154
Trial Description
Phase 2 multicenter randomized double-blind placebo-controlled study evaluating subcutaneous rademikibart as an add-on to standard therapy in adults with an acute COPD exacerbation and type 2 inflammation. The primary endpoint is treatment failure rate within 28 days after randomization.